Table: AEs, SAEs and deaths
| Glycopyrronium, N=740, n (%) | Tiotropium, N=737, n (%) | |
| Total AEs | 694 (94) | 686 (93) |
| AEs leading to permanent discontinuation of study drug | 86 (12) | 67 (9) |
| Total SAEs | 179 (24) | 165 (22) |
| Deaths | 22 (3) | 25 (3) |
| Cardio- and cerebrovascular (CCV) SAEs | 25 (3) | 26 (4) |
| Atrial fibrillation/flutter events (New onset) | 6 (1) | 8 (1) |
| Major adverse cardiac events (MACE)-total | 15 (2) | 8 (1) |
| Non-fatal myocardial infarction (MI) | 6 (1) | 2 (0.3) |
| Unstable angina | 0 | 0 |
| Non-fatal stroke | 4 (1) | 2 (0.3) |
| Heart failure requiring hospitalization | 3 (0.4) | 3 (0.4) |
| Coronary revascularization (CABG or PCI) | 4 (1) | 2 (0.3) |